Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Non-Current Deferred Tax Liability (2018 - 2025)

Historic Non-Current Deferred Tax Liability for Ligand Pharmaceuticals (LGND) over the last 14 years, with Q3 2025 value amounting to $22.7 million.

  • Ligand Pharmaceuticals' Non-Current Deferred Tax Liability fell 5114.0% to $22.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.7 million, marking a year-over-year decrease of 5114.0%. This contributed to the annual value of $32.5 million for FY2024, which is 5801.73% down from last year.
  • Ligand Pharmaceuticals' Non-Current Deferred Tax Liability amounted to $22.7 million in Q3 2025, which was down 5114.0% from $32.2 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Non-Current Deferred Tax Liability ranged from a high of $77.5 million in Q4 2023 and a low of $22.7 million during Q3 2025
  • Over the past 5 years, Ligand Pharmaceuticals' median Non-Current Deferred Tax Liability value was $39.5 million (recorded in 2022), while the average stood at $44.8 million.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Non-Current Deferred Tax Liability surged by 36658.28% in 2021, and later crashed by 5801.73% in 2024.
  • Ligand Pharmaceuticals' Non-Current Deferred Tax Liability (Quarter) stood at $72.3 million in 2021, then grew by 4.53% to $75.6 million in 2022, then rose by 2.5% to $77.5 million in 2023, then tumbled by 58.02% to $32.5 million in 2024, then tumbled by 30.29% to $22.7 million in 2025.
  • Its Non-Current Deferred Tax Liability was $22.7 million in Q3 2025, compared to $32.2 million in Q2 2025 and $29.4 million in Q1 2025.